Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
24
0

Year Published

2020
2020
2023
2023

Publication Types

Select...
7
1

Relationship

3
5

Authors

Journals

citations
Cited by 25 publications
(25 citation statements)
references
References 54 publications
1
24
0
Order By: Relevance
“…However, in this context, it is relevant to mention, that the preclinical screening platform in the field of ACC was inadequate for a long time, as we faced a huge lack of tumor models, with NCI-H295R as the only available cell line of human origin for more than 20 years [17]. In the current study, we have performed an extensive preclinical drug screening and subsequent mechanistical investigation based on classical chemotherapies and innovative targeted agents, using two different adrenocortical cancer cell lines: the classical NCI-H295R cell line and the more recently developed and highly drug-resistant MUC-1 cell line [11,[18][19][20][21][22][23].…”
Section: Discussionmentioning
confidence: 99%
“…However, in this context, it is relevant to mention, that the preclinical screening platform in the field of ACC was inadequate for a long time, as we faced a huge lack of tumor models, with NCI-H295R as the only available cell line of human origin for more than 20 years [17]. In the current study, we have performed an extensive preclinical drug screening and subsequent mechanistical investigation based on classical chemotherapies and innovative targeted agents, using two different adrenocortical cancer cell lines: the classical NCI-H295R cell line and the more recently developed and highly drug-resistant MUC-1 cell line [11,[18][19][20][21][22][23].…”
Section: Discussionmentioning
confidence: 99%
“…Another study has proven that nilotinib, a selective tyrosine kinase receptor inhibitor, as a cytotoxic drug that combined with ERK inhibitors deserves to be tested as a novel therapy options in ACC patients [ 224 ]. Palbociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved as a cancer therapy, causes a concentration- and time-dependent reduction in ACC cell viability, which was more pronounced in the cells in line with higher CDK4 expression [ 225 ]. Palbociclib in combination with insulin-like growth factor 1/insulin receptor inhibitor linsitinib shows an additive effect [ 225 ].…”
Section: Treatment Optionsmentioning
confidence: 99%
“…Palbociclib, the first cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved as a cancer therapy, causes a concentration- and time-dependent reduction in ACC cell viability, which was more pronounced in the cells in line with higher CDK4 expression [ 225 ]. Palbociclib in combination with insulin-like growth factor 1/insulin receptor inhibitor linsitinib shows an additive effect [ 225 ]. Hedgehog Receptor Patched is expressed in ACC and contributes to doxorubicin efflux and treatment resistance [ 226 ].…”
Section: Treatment Optionsmentioning
confidence: 99%
“…Inactivating mutations in the tumour suppressor TP53 occur in at least another 20% of sporadic ACC [11]. Increased expression of IGF2 (Insulin like growth factor 2) that is found in ~90% of ACC [14][15][16] provided the rationale for a phase III clinical trial with the selective small molecule IGF-1R inhibitor linsitinib but the results were disappointing [17]. Only few patients derive clinical bene t from multi-tyrosine kinase inhibitors that have been clinically tested [18].…”
Section: Introductionmentioning
confidence: 99%
“…The rst paediatric ACC patient-derived xenograft (PDX) model (SJ-ACC3) was reported by Pinto et al [33] and in 2016, Hantel and colleagues successfully developed the rst adult ACC PDX and established a respective cell line, termed MUC-1 [34]. The publication in 2018 of two additional PDXderived ACC cell lines including one from a LS patient [35] increased the number of available human ACC cell lines to four, which now allows comparative studies that better re ect the genetic heterogeneity of ACC [16,[36][37][38].…”
Section: Introductionmentioning
confidence: 99%